This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition.
The current landscape of protein drugdevelopment is characterised by accelerated timelines where new drugs are approved in months rather than years. In recent years, the biopharmaceutical industry has identified rapid Toxicology (Tox) material supply as the new critical path to IND readiness.
However, with this kind of promise comes more scientific, ethical and financial questions that healthcare providers and drugdevelopment professionals must seriously consider. As more people take them and their uses grow, so does their potential. Its new CEO has to figure out what’s next.
These are exactly the applications where current generative AI … completely excels and where we see similar gains in drugdevelopment and scientific review internally at Lantern Pharma,” he said. Bloomberg 23andMe’s DNA Data Gets Boosted $305 Million Bid in New Auction View all Events 17 JUN Webinar | 10:30 a.m.
I sequenced the complementary DNA (cDNA) encoding RAS GTPase Activating Protein, a protein known that regulates cell growth, differentiation and survival of cells; mutations in these proteins are linked to cancer. My proudest achievement is my leadership journey building legacy organisations, processes and tools in clinical operations.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content